PK-PD modelling in patients with CIDP.
Date published: May 24, 2024
The optimal maintenance dosing regimen of intravenous immunoglobulin (IVIg) varies between patients with CIDP.
At present, there is only limited information available on the pharmacokinetics (PK) of IVIg treatment in patients with CIDP.
In this study we want to describe the PK of IVIg induction and maintenance treatment in patients with CIDP using non-linear mixed effects modelling (NONMEM).
We aim to understand whether monitoring serum IgG in patients with CIDP can be used to optimize treatment, and whether the PK of IVIg affects the variability in treatment response.
A list of research articles
-
The role of B lymphocytes in the progression of chronic immune-mediated neuropathies
-
Study on CIDP
In addition, I am studying the role of B lymphocytes in the progression of chronic immune-mediated neuropathies, including Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Autoimmune Nodopathy (AN). Through this research, we strive to enhance diagnostics, clinical care, and treatment options for patients affected by these conditions.
-
-
Detecting anti-paranodal antibodies
-
Study on GBS
My research primarily focuses on investigating novel pathogenic antibodies in paranodal regions associated with immune-mediated neuropathies. The aim of my project is to improve diagnostic methods for detecting anti-paranodal antibodies and to determine the prevalence of these harmful autoantibodies in patients with Guillain-Barré Syndrome (GBS).
-
-
Time to treatment study
-
Study on GBS
In this project, we aim to describe the current practice of time to treatment. We also assess the association with functional outcome in patients with GBS who received first-line treatment with intravenous immunoglobulin or plasma exchange. This study is performed using data from the International GBS Outcome Study (IGOS).
-
